Obinutuzumab en combinación con bendamustina para el tratamiento de la variante de leucemia de células peludas: un informe de caso y una revisión de la literatura
Video Experimental Relacionado
Updated: Sep 9, 2025

15:04
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.3K
Junjun Bai1, Yi Zhang2,3, Kangqi Lv3
1Department of Hematology, Jiaozuo People's Hospital, Jiaozuo, Henan, China.
Frontiers in oncology
|September 3, 2025
Resumen
La variante de leucemia de células ciliadas (HCL-v) es una leucemia de células B agresiva. Una combinación de obinutuzumab y bendamustina logró una remisión completa en un paciente con HCL-v.
Área de la Ciencia:
- Hematología
- En el campo de la oncología
Sus antecedentes:
- La variante de leucemia de células pilosas (HCL-v) es una leucemia B rara y agresiva.
- HCL-v exhibe una respuesta pobre a las terapias convencionales en comparación con la leucemia de células ciliadas clásica (HCL-c).
Palabras clave:
BRAF de tipo salvaje- ¿Qué es eso?Variante de la leucemia de células peludasObinutuzumab y sus derivadostratamiento dirigidoMás Videos Relacionados
Videos de Conceptos Relacionados
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K

